Home » Business News » 2013 » April » April 26, 2013

Sobi publishes Report for the First Quarter 2013

April 26, 2013 - London

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2013. Revenues for the quarter totalled MSEK 528.5 (506.7), with continued momentum across the commercial portfolio and several significant advances in the pipeline.

Business Highlights

  • Received FDA approval of Kineret® for the treatment of NOMID.
  • Presented new phase 3 Haemophilia data, reinforcing long-lasting protection from bleeding for patients.
  • Received EMA approval to manufacture Kineret drug substance with partner Boehringer Ingelheim.
  • Entered into three key partnerships which further strengthen the partner network across the portfolio.

Financial Highlights

  • Total revenues increased by 4 percent to MSEK 528.5 (506.7). Adjusted for one-time items in the prior year, revenues increased 12 percent.
  • Gross margin increased to 57 percent (51) driven by efficiency gains in production and completion of technology transfer for Kineret.
  • Ended the quarter with a cash position of MSEK 401.2.
  • Outlook for 2013 remains unchanged.

"The quarter demonstrated continued commercial momentum, with 4 percent growth year over year and expansion of our Key Therapeutic Areas of Inflammation and Genetics in existing and new markets," said Geoffrey McDonough, CEO and President. "In addition, our pipeline posted several significant events including the FDA approval of Kineret for the treatment of NOMID and the release of additional data from the phase 3 trials of our long-lasting recombinant clotting factors for Haemophilia."


Sobi's report for the first quarter 2013 can be found on

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late-stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at

For more information please contact

Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 410 71 80 T: +46 8 697 20 00

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 26 April 2013 at 8:00 CET

Sobi Report for the First Quarter 2013

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE



Comment on this story